Olaparib, PARP1 inhibitor in ovarian cancer

Author： Marchetti Claudia   Imperiale Ludovica   Gasparri Maria Luisa   Palaia Innocenza   Pignata Sandro   Boni Terenzio   Bellati Filippo   Benedetti Panici Pierluigi  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.10, 2012-10, pp. : 1575-1584

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Parp Inhibitors for the Treatment of Ovarian Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 9, 2018-11 ,pp. : 877-893

Bentham Science Publishers

Access to resources Recommend Favorite

The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell

By  

Current Pharmaceutical Biotechnology, Vol. 19, Iss. 6, 2018-05 ,pp. : 506-513

Bentham Science Publishers

Access to resources Recommend Favorite

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

By Samol Jens  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1493-1500

Springer Publishing Company

Access to resources Recommend Favorite

PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials

By  

Current Drug Targets, Vol. 19, Iss. 1, 2018-01 ,pp. : 21-37

Bentham Science Publishers

Access to resources Recommend Favorite

The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility

By  

Current Pharmacogenomics, Vol. 3, Iss. 1, 2005-01 ,pp. : 9-19

Bentham Science Publishers

Access to resources Recommend Favorite